Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zydelig in B-cell Malignancies as Post-Autologous Transplant Remission Maintenance
NCT03133221Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2017
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in non-Hodgkin lymphoma (NHL), sponsored by University of Maryland, Baltimore. Primary endpoint: Discontinuation Rate Due to Zydelig-related Adverse Events at 1 year. Started Oct 2017; status: completed.
02
Drugs
idelalisib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03133221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133221.